Published in FEBS Lett on April 10, 2003
Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. J Clin Invest (2010) 1.77
Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood (2010) 1.15
Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin Exp Pharmacol Physiol (2010) 1.11
High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J Lipid Res (2013) 1.09
Apolipoprotein E4 in macrophages enhances atherogenesis in a low density lipoprotein receptor-dependent manner. J Biol Chem (2007) 0.94
Human scavenger receptor class B type II (SR-BII) and cellular cholesterol efflux. Biochem J (2004) 0.93
Apolipoprotein E4 impairs macrophage efferocytosis and potentiates apoptosis by accelerating endoplasmic reticulum stress. J Biol Chem (2012) 0.93
Apolipoprotein E inhibits toll-like receptor (TLR)-3- and TLR-4-mediated macrophage activation through distinct mechanisms. Biochem J (2010) 0.88
Genetic variants of ApoE and ApoER2 differentially modulate endothelial function. Proc Natl Acad Sci U S A (2014) 0.85
Sorting nexin 17 regulates ApoER2 recycling and reelin signaling. PLoS One (2014) 0.80
Apolipoprotein E receptor-2 deficiency enhances macrophage susceptibility to lipid accumulation and cell death to augment atherosclerotic plaque progression and necrosis. Biochim Biophys Acta (2014) 0.79
Targeted In Situ Gene Correction of Dysfunctional APOE Alleles to Produce Atheroprotective Plasma ApoE3 Protein. Cardiol Res Pract (2012) 0.78
Patients with chronic three-vessel disease in a 15-year follow-up study: genetic and non-genetic predictors of survival. Medicine (Baltimore) (2014) 0.76
Apolipoprotein E Receptor 2 Mediates Activated Protein C-Induced Endothelial Akt Activation and Endothelial Barrier Stabilization. Arterioscler Thromb Vasc Biol (2016) 0.76
apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL. J Lipid Res (2014) 0.75
Clearance of beta-amyloid is facilitated by apolipoprotein E and circulating high-density lipoproteins in bioengineered human vessels. Elife (2017) 0.75
Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol (2007) 1.68
Spectroscopic photoacoustic imaging of lipid-rich plaques in the human aorta in the 740 to 1400 nm wavelength range. J Biomed Opt (2012) 1.62
Use of internally nuclease-protected single-strand DNA oligonucleotides and silencing of the mismatch repair protein, MSH2, enhances the replication of corrected cells following gene editing. J Gene Med (2009) 1.05
Human scavenger receptor class B type II (SR-BII) and cellular cholesterol efflux. Biochem J (2004) 0.93
Development of therapeutic splice-switching oligonucleotides. Hum Gene Ther (2014) 0.88
Exon skipping of hepatic APOB pre-mRNA with splice-switching oligonucleotides reduces LDL cholesterol in vivo. Mol Ther (2013) 0.86
Oligonucleotide-directed gene-editing technology: mechanisms and future prospects. Expert Opin Biol Ther (2012) 0.83
Correction of the neuropathogenic human apolipoprotein E4 (APOE4) gene to APOE3 in vitro using synthetic RNA/DNA oligonucleotides (chimeraplasts). J Mol Neurosci (2005) 0.82
Human apolipoprotein E expression from mouse skeletal muscle by electrotransfer of nonviral DNA (plasmid) and pseudotyped recombinant adeno-associated virus (AAV2/7). Hum Gene Ther (2008) 0.82
ApoE gene therapy to treat hyperlipidemia and atherosclerosis. Curr Opin Mol Ther (2006) 0.82
Failure to generate atheroprotective apolipoprotein AI phenotypes using synthetic RNA/DNA oligonucleotides (chimeraplasts). J Gene Med (2003) 0.80
Two novel missense mutations in ABCA1 result in altered trafficking and cause severe autosomal recessive HDL deficiency. Biochim Biophys Acta (2004) 0.79
Apolipoprotein E delivery by peritoneal implantation of encapsulated recombinant cells improves the hyperlipidaemic profile in apoE-deficient mice. Biochim Biophys Acta (2005) 0.79
Quantification of apolipoprotein E receptors in human brain-derived cell lines by real-time polymerase chain reaction. Neurobiol Aging (2005) 0.79
Preliminary evaluation of a self-complementary AAV2/8 vector for hepatic gene transfer of human apoE3 to inhibit atherosclerotic lesion development in apoE-deficient mice. Atherosclerosis (2008) 0.78
Targeted In Situ Gene Correction of Dysfunctional APOE Alleles to Produce Atheroprotective Plasma ApoE3 Protein. Cardiol Res Pract (2012) 0.78
How does interferon inhibit HCV cell entry? Gut (2008) 0.75
Adeno-associated virus serotypes 7 and 8 outperform serotype 9 in expressing atheroprotective human apoE3 from mouse skeletal muscle. Metabolism (2010) 0.75
Oligonucleotide-mediated gene editing is underestimated in cells expressing mutated green fluorescent protein and is positively associated with target protein expression. J Gene Med (2012) 0.75
Lack of RNA-DNA oligonucleotide (chimeraplast) mutagenic activity in mouse embryos. Mol Reprod Dev (2005) 0.75
Assessment of selected bioretention blends for nutrient retention using mesocosm experiments. J Environ Qual (2014) 0.75